Novartis embraces multi-indication development model
This article was originally published in Scrip
Executive Summary
Novartis is moving away from what the company dubbed the "traditional" drug development model towards one where multiple indications are explored in parallel prior to regulatory assessment, the company stated at a recent event in Basel, Switzerland.